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Dose Time Response Modeling of Neurobehavioral Screening Data: 
Application of Physiologically Relevant Parameters to Allow for Dose 
Dependent Time of Peak Effects 
 
 
Michael Raymond Wessel 
 
 
ABSTRACT 
 
 In collaboration with the United States Environmental Protection 
Agency (USEPA), the University of South Florida Health Risk 
Methodology Group has developed dose-time-response models to 
characterize neurobehavioral response to chemical exposure. The 
application of dose-time-response models to neurobehavioral 
screening tests on laboratory animals allows for benchmark dose 
estimation to establish exposure limits in environmental risk 
assessment. This thesis has advanced dose-time-response modeling 
by generalizing a published toxico diffusion model to allow for dose 
dependent time of peak effects. To accomplish this, a biphasic model 
was developed which adopted the effect compartment model paradigm 
used in pharmacokinetics/pharmacodynamics to estimate a 
distributional rate constant to account for dose related variation in the 
time of peak effect. The biphasic model was able to describe dose-
dependent time of peak effects as observed in the data on acute 
exposure to parathion and adequately predicted the observed 
response. However, the experimental design appeared insufficient in 
statistical power to confirm statistical significance for each parameter 
of interest. Motivated by the question of what design requirement 
might be necessary to validate the biphasic model, Monte Carlo 
simulation was adopted. Simulations were performed to assess the 
efficacy and efficiency of various experimental designs for detecting 
and evaluating some critical characteristics of the biphasic model, 
including the TOPE. The results of simulation suggest that the location 
of measurement times around the TOPE have important implications 
for assessing the statistical significance of the parameter that 
describes dose-dependent TOPE and that the mean squared error of 
the parameter estimator was improved most when testing times were 
 viii 
chosen to bracket the TOPE. While dose dependent time of peak 
effects has underlying physiological mechanisms such as synergistic or 
capacity limited kinetics, the biphasic model estimates these 
physiological properties through a mathematical function which may 
be physiologically relevant but does not necessarily define 
physiological mechanisms underlying the response. However, if 
verified through further testing, the biphasic model may contribute to 
the USEPA’s aim of developing physiologically relevant dose-response 
models for assessing risk of neurotoxicity with repeated measurements 
of response.  
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Chapter One 
Introduction 
Chemical exposure has become a certainty of human life in the 
21st century. In fact, it is difficult to imagine a day goes by in which 
one is not exposed to a chemical, natural or synthetic, about which 
there is some uncertainty of risk. Formal attempts to characterize the 
risks associated with chemical exposure date back to Hippocrates 
(ancient 400 BC) who developed toxicological principles related to 
clinical observations on the bioavailability and absorption of common 
therapies and poisons. Paracelsus (~1500 AD) is credited with the idea 
that all substances are poisons and it is the dose that determines its 
potential risk and benefit.  In modern times, exponential growth in the 
production of chemicals occurred as a consequence of the industrial 
revolution and World War II and in the United States led to the 
establishment of regulatory agencies such as the Food and Drug 
Administration and later the Environmental Protection Agency (US 
EPA). Because of the many natural and synthetic chemicals introduced 
in today’s environment, governmental agencies throughout the 
industrialized world have become keenly interested in assessing the 
potential risks to humans from toxic agents (US EPA, 1998). In the 
 2 
US, the EPA has registered more than 65,000 chemical substances 
manufactured, imported, or processed in the United States under the 
Toxic Substance Control Act (TSCA) (US EPA, 1996). Chemical 
exposure has become one of the ten leading causes of workplace 
disorder (Anger, 1984) and the potential for adverse effects on the 
nervous system is becoming common in the workplace as 
approximately 70 chemicals of known neurotoxic potential have 
potential exposure to more than 1 million workers (Anger,1990).  
1.1 Health Risk Assessment  
Environmental risk assessment is an emerging field that relies on 
three basic assessment principles: exposure assessment, hazard 
characterization, and risk quantification (McCarty and Mackay, 1993).  
The EPA’s National Center for Environmental Assessment (NCEA) 
conducts risk assessment for an array of health effects that may result 
from exposure to environmental agents. This process includes a 
thorough evaluation of all the available data as well as conducting 
scientific experiments to understand the relationship between 
exposure and risk. Historically, these analyses have been done very 
differently for cancer and non-cancer health effects because of 
perceived differences in the mechanistic underpinnings of cancer and 
other toxic effects. As our understanding of the underlying biology of 
toxic effects has grown, however, the apparent differences between 
 3 
cancer and non-cancer effects have lessened to the point where it 
seems reasonable to develop quantitative methods based on similar 
considerations for all types of health effects, and to make approaches 
to risk assessment as consistent across health endpoints as our 
current mechanistic understanding allows (US EPA, 2000). 
Neurotoxicity risk assessment is one area in particular where the EPA 
has expressed the need for consistent guidance on how to evaluate 
data on neurotoxic substances and assess their potential to cause 
transient or persistent and direct and indirect effects on human health.  
1.2 Neurotoxicity 
Neurotoxicity is defined as an adverse change in the structure or 
function of the central and/or peripheral nervous system following 
exposure to a chemical, physical or biological agent (Tilson, 1990). 
The central nervous system is particularly vulnerable to chemical insult 
and has limited ability to regenerate. Functional neurotoxic effects 
include adverse changes in somatic/ autonomic, sensory, motor and/or 
cognitive function (US EPA, 1998). The effects can be transient (the 
organism returns to pre-exposure condition) or persistent (the 
organism is permanently and adversely changed by exposure). 
However, even transient effects can signify underlying resultant 
damage to the organism (US EPA, 1998). Animal studies make up the 
largest portion of controlled exposure assessments and allow for the 
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use of high concentrations of chemicals to be administered to achieve 
responses that may define the mechanism of action as well as the 
magnitude of response to chemical exposure. Neurotoxic screening 
tests such as the Functional Observational Battery (FOB) test (Moser 
et al., 1995, 1997a), along with neuro-physiological, biochemical, 
neuro-pathological and neuro-endocrinological studies are now being 
used by the EPA as an overall strategy to detect the full range of 
chemical induced alterations in the structure and function of the 
nervous system.   
 The advancement of neurotoxicity testing methods and 
experimental design has coincided with advances in statistical 
methodologies and computer applications to allow for more effective 
methods of performing risk assessments on neurotoxins. A significant 
advance in neurotoxicity risk assessment is the use of benchmark dose 
(BMD) methodologies for establishing safety levels of chemical 
exposure (US EPA, 2000). While traditional analysis of FOB data has 
used Analysis of Variance (ANOVA) to set a No Observed Adverse 
Effects Level (NOAEL), dose-time-response models provide continuous 
estimation of response over the time course of the study providing 
beneficial information for BMD estimation. 
The University of South Florida’s Health Risk Assessment 
Methodology Group (HRAMG) has been working to develop new 
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statistical methods for explicit dose-time-response models (DTR) of 
the FOB data, which may serve as the foundation for benchmark dose 
estimation. The development of explicit DTR models to describe 
neurotoxic potential of chemical exposure has progressed from strictly 
mathematical models such as polynomial models to those 
incorporating simple toxicokinetics. The potential for physiologic 
interpretation enhances comparability with other available data and 
increases confidence in the interspecies extrapolation of results of 
these screening tests to characterize potential risk to human health. 
Zhu (2005a) and Zhu et al. (2005b,c) have developed a family of 
dose-response models and illustrated their application through several 
published datasets generated from the EPA Superfund study (Moser et 
al, 1995) and a study conducted in collaboration with the International 
Program on Chemical Safety (IPCS) (Moser et al. 1997a). These 
models incorporate basic toxicokinetic principles into a family of 
mathematical models in consideration of the physical properties 
underlying responses to chemical exposure observed in the FOB data. 
Zhu (2005 b,c) found that the toxico diffusion model often 
satisfactorily described the observed dose-response relationship in FOB 
data and is useful in application of benchmark dose estimation 
methods. While the toxico diffusion model has proven robust in 
describing FOB data, it is limited in describing the full possible range of 
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dose related response to acute exposure. Most importantly this model 
is limited by imposing a dose independent Time of Peak Effect (TOPE) 
across every exposure level.  
1.3 Thesis Objectives 
The first objective of this thesis was to expand on a published 
toxico-diffusion function used to model neurobehavioral screening data 
by considering a situation where the TOPE may take on dose-
dependent characteristics. Through the incorporation of a dose-
dependent distributional parameter, this thesis proposes a “biphasic 
diffusion” model and illustrates the utility of this model on the analysis 
of a FOB dataset on the motor activity of laboratory rats exposed to 
the organophosphate pesticide parathion.  
A second objective of the thesis was to investigate the study 
design requirements necessary to recover the key characteristics of 
the biphasic model, especially dose-dependent time of peak effect. 
Monte Carlo simulation was adopted to explore the potential FOB 
testing times as well as sample size with respect to the efficiency and 
effectiveness of recovering key components of the biphasic model. 
Various designs were compared using statistical measures of bias, 
power, mean squared error, and confidence interval. Utility of 
alternative study designs may contribute to the USEPA’s aims toward 
 7 
using dose-response modeling, particularly with physiologically 
relevant models, to assess potential risks of chemical exposure to 
human health. 
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Chapter 2 
Neurobehavioral Screening Tests  
2.1 Screening Tests 
Screening tests for neurotoxicity represent the most 
fundamental level of investigation for forecasting potential 
neurotoxicity in animal studies (WHO 1986). Screening tests are 
widely used because they are simple, rapid and economical.  A battery 
of measurements is acquired with these tests that include 
measurements of behavioral endpoints representing neuro-
physiological, neuro-muscular, autonomic and sensorimotor functions. 
Behavioral endpoints reflect the integration of various functional 
components of the nervous system and are often used as surrogates 
for mechanistic processes involved in a subjects response to exposure 
of a chemical agent. The EPA’s testing guidelines developed for the 
Toxic Substances Control Act (TSCA) and the Federal Insecticide, 
Fungicide, and Rodenticide Act described the use of neurobehavioral 
screening tests and established protocols and procedures used in these 
experimental designs (US EPA, 1991). Since that time the protocols 
and procedures have been refined and are evolving to become a 
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standardized first tier screening method for neurotoxicity (US EPA, 
1998). These toxicological studies, known as Functional Observational 
Battery (FOB) tests, are simple to implement, relatively non-invasive 
and generate behavioral change rapidly.  
2.2 IPCS Functional Observational Battery Tests 
This thesis utilizes data from a Functional Observational Battery 
(FOB) as described in Moser et al. (1997a) and implemented in the 
IPCS’ collaborative study. For acute exposure, the study protocol uses 
5 dose levels including a control group and 4 testing times (including a 
baseline measurement) to assess time-related response to chemical 
exposure. The dose levels and the second testing time were 
determined via a dose range finding study. Given the cooperative 
nature of the IPCS sponsored studies several laboratories participated 
in these studies yielding several independent estimates of dose-
response for many of the chemicals tested. 
Prior to initiation of the FOB testing a dose range finding study 
was performed to determine the dosing regime and testing times for a 
hypothesized time of peak chemical effect (TOPE) (Moser et al., 
1997b). The starting dose was chosen based loosely on published 
estimates of the LD50 (dose which would be lethal to 50% of the 
subjects). Three doses at constant intervals above and below the 
starting dose were used for a seven day survival study to determine 
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the top nonlethal dose to use in the FOB studies.  The dose levels used 
for the FOB designs were then 100%, 50% 25% and 12.5% of the top 
nonlethal dose. A separate pilot study was then conducted to estimate 
the TOPE using gait and arousal scores.  Thus, the TOPE estimated for 
gait and arousal scores were taken to represent a hypothesized TOPE 
for all neurobehavioral endpoints. 
Ten animals were randomly assigned to each dose group for the 
FOB studies. Testing times were established such that a FOB was 
conducted prior to exposure and at 2-3 subsequent time points after 
exposure. The first post-exposure testing time was conducted to 
correspond with the TOPE of the chemical being tested. Subsequent 
tests were performed at one day and then one week after exposure. 
Post exposure test times generally did not exceed one week.  
The FOB response variables consisted of 25- 30 non-invasive 
measures designed to assess behavioral alterations with respect to a 
wide range of neurobiological functions, including sensory, motor and 
autonomic functions, excitability, neuromuscular strength, and activity 
level. The entire battery of tests required approximately 6-8 minutes 
per rat. Assessment of motor activities was used in conjunction with 
the FOB because of its long history of use for evaluating behavioral 
effects of chemicals (MacPhail et al., 1989). Motor activity counts 
represent a broad class of behaviors involving coordinated 
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participation of sensory, motor, and integrative processes. Neurotoxic 
agents can lead to either increases or decreases in motor activity 
counts and organophosphate pesticides such as parathion, the 
chemical studied in this thesis, have been shown to decrease motor 
activity counts in neurobehavioral screening studies (USEPA, 1998). 
The apparatus for motor activity test was left to the discretion of 
participating laboratories, provided several criteria were met (Moser et 
al., 1997a). This thesis used parathion motor activity counts to 
illustrate fitting the biphasic toxico-diffusion model to neurobehavioral 
screening data.  
2.3 Assessment Methodologies 
 The USF Health Risk Assessment Methodology Group (HRAMG) 
has used the FOB to develop and test several classes of mathematical 
models to predict neurobehavioral response to chemical exposure. Liu 
(2000) developed polynomial models for continuous FOB outcomes; 
Woodruff (2001) developed a diffusion model that is flexible in 
describing both transient and persistent nonlinear dose-response 
relationships seen in the FOB data; Zhu (2001) tested these models on 
a large number of FOB datasets from both the EPA Superfund and the 
IPCS studies. More recently Zhu (2005a) developed a class of 
mathematical models that allow for incorporation of toxicokinetics, and 
in a series of reports (Zhu et al. 2005a,b) applied these models to the 
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FOB datasets and illustrated their use in benchmark dose estimation. 
Common in these statistical analyses was the use of random effects to 
adjust for biological variation in responses among animals. These 
models performed well for describing the dose-response patterns 
observed in the FOB studies. However, physiological relevance of these 
models relies on simplifying assumptions such as linear or single-
compartment kinetics. It would be beneficial to derive models capable 
of describing exposure related response as well as incorporate 
parameters that estimate well known physiological phenomena that 
regulate the time course of a chemicals presence in the body and its 
affect on the observed response when the system displays 
nonlinearities such as nonlinear uptake or saturation kinetic processes. 
Understanding of this process begins with knowledge of how the body 
processes the chemical (pharmacokinetics/toxicokinetics) and 
subsequent characterization of how the concentration of the chemical 
affects the organism of study (pharmacodynamics/toxicodynamics).  
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Chapter 3 
Pharmacokinetics and Pharmacodynamics 
In this thesis, references are made to pharmacokinetic and 
pharmacodynamic (PK/PD) modeling techniques to develop a 
background on which the generalized biphasic toxico diffusion model 
was based. It should be noted that while the terms pharmacokinetics 
and toxicokinetics have essentially parallel meaning in their respective 
fields, in the strictest sense the former term should be restricted to the 
field of pharmacology. Since much of the literature devoted to kinetic 
and dynamic properties of chemical exposure has arisen from the field 
of pharmacology, we define the modeling approach using the PK/PD 
modeling paradigm and apply the biphasic model to a toxicological 
study.  
3.1 Compartmental Pharmacokinetics 
Orthodox pharmacokinetic and toxicokinetic studies deal with 
changes of drug concentrations in the plasma or an organ over time in 
an attempt to describe how the body absorbs, distributes and 
eliminates a drug (Torda et al. 1994). The compartmental approach to 
pharmacokinetic estimation views the body as being composed of a 
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number of pharmacokinetically distinct compartments. Each 
compartment can be thought of as an imaginary space in the body 
representing a combination of various tissues and organs, among 
which the drug interacts. Anatomical composition of the compartment 
is unknown and in most cases its analysis is often of little value (Kwon 
2002). Compartmental models are designed to provide a conceptual 
understanding of distributional behaviors of a drug between the 
plasma and other tissues or organs in the body and estimate various 
pharmacokinetic parameters including plasma concentrations, 
apparent volumes of distribution and rates governing elimination and 
clearance. It is recognized that these compartment models, while 
estimating physiological properties, still represent empirical fits to the 
data. However, the physiological interpretations are important for 
extrapolating information from animal studies to regulatory data on 
human health (US EPA 1998). Consider, for example, the simplest of 
pharmacokinetic models describing IV bolus injection of a substance 
into the circulatory system and subsequent elimination (Ke) from the 
body (Figure 1).  
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Concentration of the chemical in the compartment is highest 
immediately after injection and concentration at any time t is governed 
by a single exponential rate of elimination:  Cp(t) = C0*e
(-K
e
*t) 
Where; 
Cp(t) = Concentration in the circulatory system at time t 
C0 = Concentration of chemical immediately after IV bolus injection 
e(-Ke*t) = an exponential elimination rate constant. 
  
This first order, mono-exponential function is typically used to model 
plasma concentration versus time curves with direct injection into a 
central compartment yielding estimates of compartment volume and 
chemical elimination. One compartment behavior of plasma 
concentration does not necessarily imply that the chemical is at the 
same concentration in all the tissues and organs in the body. Rather, 
Ke 
Cp
Chemical
Figure 1. Illustration of simple one compartment pharmacokinetic 
model 
 16 
this implies that the concentrations are in instantaneous equilibrium 
with those in the plasma upon drug administration. 
 An expansion of the one-compartmental approach to 
pharmacokinetic modeling is to allow for the distribution of the 
chemical from the plasma compartment into a peripheral compartment 
(brain, muscle tissue, etc). When distribution of a chemical from the 
plasma into certain organs or tissues is substantially different from the 
central compartment, multi-compartment models allow for the 
incorporation of one, or several, peripheral compartments (Figure 2).  
 
 
 
The two compartment model is typically defined where the 
administered chemical is delivered and eliminated from the central 
compartment and distribution between the central and peripheral 
compartments is controlled via two distribution micro-constants (K12 
Chemical 
C1(t) C2(t) 
K12 
K21 Ke
Ka 
 
Figure 2. Two compartment PK model describing the 
pathway of chemical introduction and elimination from 
an organism 
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and K21) characterized by the distribution constant Ka (Gabrielsson and 
Weiner 2000).  When these rate constants reach a steady state, then 
the distribution of the chemical reaches equilibrium and the 
mechanism governing concentration in the central compartment is 
controlled through the elimination rate Ke . Methods of estimating the 
concentration in the central compartment via a two compartment 
paradigm include the bi-exponential function  
Cp(t)=θ1e-Ka*t + θ2e-Ke*t 
 where Ka  represents the distribution phase from the plasma that 
includes absorption into the second compartment and Ke represents 
the post equilibrium or terminal elimination phase governed by 
elimination of the chemical from the central compartment. Chemical 
concentration in the plasma is highest immediately after injection in 
the two-compartment model and behaves similarly to the one 
compartment model except initially when absorption into the second 
compartment causes an accelerated depletion of the chemical 
concentration from the central compartment (Figure 3).  
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3.2 Nonlinear Kinetics 
Any pharmacokinetic process of a chemical (i.e. absorption, 
distribution, metabolism or excretion) that cannot be described with 
first order (linear) kinetics can be considered nonlinear kinetics. 
Nonlinear kinetics implies deviations in the rate of change in chemical 
concentration from first order kinetics in a manner that is dose and /or 
time dependent. Dose-dependent nonlinearity can be due to any 
carrier mediated process such as metabolism or active transport that 
displays transient saturation or cooperativity at high concentrations 
(Kwon 2002). Dose-dependent kinetics may be observed as a 
Figure 3.  Bi-exponential decline of concentration in the 
central compartment after iv bolus injection when chemical 
distribution can be described using two-compartment 
model (Taken from Kwon 2002). 
Distribution phase
Terminal elimination phase
Time
Log Cp(t)
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stimulated or suppressed response function where increases in 
chemical concentration result in non additive increases in 
concentrations in peripheral compartments in either a synergistic or 
capacity limited manner.  
3.3 Pharmacodynamics 
To this point we have considered the relationship between 
administration of chemical into an animal and some of the basic 
pharmacokinetic parameters describing the time course of chemical 
concentration in biological fluids. Obviously, there are many other 
factors, known and unknown that govern the specific “effects” of 
chemical exposure on the exposed subject. The study of 
Pharmacodynamics (PD) is designed to characterize the effect of the 
chemical on the body. If concentration in the plasma and effect site is 
in rapid equilibrium, PD models may adequately serve to estimate the 
pharmacological effects of chemical in the body. These models are 
valuable in capturing the nonlinear aspects of response patterns often 
seen in pharmacological experiments and in estimating various 
pharmacodynamic parameters used for establishing dosing regimens in 
clinical studies (Gabrielsson and Weiner 2000). However, 
advancements in the field of pharmacology and toxicology have 
included the realization that more often in in vivo experiments, 
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pharmacological effects take time to develop. 
Pharmacokinetic/pharmacodynamic (PK/PD) models attempt to link 
concentration in the plasma and response to chemical exposure by 
linking the pharmacokinetic properties of a chemical to the biological 
response observed at the effect site. While direct and simultaneous 
measurement of chemical concentration at the effect site and its 
pharmacological effect is the most desirable approach to reveal the 
true pharmacodynamic profiles of a substance, it is seldom feasible to 
measure chemical concentration at the effect site because of limited 
accessibility and availability to the site (Kwon, 2002).  
3.4 Pharmacokinetic/Pharmacodynamic Modeling 
Pharmacokinetic/Pharmacodynamic modeling has become a 
common mechanism for elucidating the chemical/effect relationship 
when a distributional delay exists or when the system is subject to 
time or dose-dependent kinetic and/or dynamic changes. Effect 
compartment models are a class of PK/PD models used to account for 
differences in concentration between the plasma and effect 
compartments by introducing an equilibrium rate constant Keo (Holford 
and Sheiner, 1981) (Figure 4).  
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This rate constant Keo eliminates the discrepancies observed between 
the plasma and effect compartments resulting in an estimate of 
chemical concentration (Ce) in the effect compartment. For example, 
an equation used to link a single compartment pharmacokinetic 
equation assuming intravenous injection of drug into the central 
compartment to a pharmacodynamic model is the following biphasic 
kinetic equation.  
− −= −−( ) ( )
e eoK t K teoe
eo e
KD
C t e e
V K K  
Where: 
Ce(t)=Concentration in the effect site at time t 
D
V
= dose/volume equivalent to Ce(t=0) 
Ke = Elimination rate for the central compartment 
Chemical 
Cp(t) 
K eo Effect 
Ke 
Ce(t) 
Figure 4. Illustration of the Effect-Compartment model. 
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Keo = Distribution rate for the effect compartment 
 
This model is used to account for differences between the central and 
effect compartments caused by distributional delay (Kwon 2002). This 
function becomes central to the biphasic toxico-diffusion model 
discussed in Chapter 5. 
Once Ce(t) is derived, effect compartment models can then be used to 
estimate pharmacodynamic response. Since observed response can be 
represented by either an elevation of the measured effect or an 
inhibition of the effect, these effect compartment models are classified 
as either Emax (elevated response) or Imax (inhibited response) models.  
 )(
)()(
50
max
tCEC
tCEtE
e
e
+=  
A baseline response E0 can be added to reflect change from baseline. 
The term Emax in the equation corresponds to the theoretical maximum 
effect while EC50 represents the “half-life” time at which the effect is 
half of the maximum response. A power term (n) can be added to the 
Emax or Imax models making them sigmoid models (sometimes referred 
to as the Hill equation) to  represent sigmoid concentration versus 
effect curves related to carrier mediated processes such as enzyme 
cooperativity (negative or positive) affecting the concentration effect 
curve.  
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Exponents less than 1 increase the initial slope of the curve while an 
exponent greater than 1 makes the curve more shallow initially. These 
curves converge around the EC50 value and then cross with larger 
exponents reaching Emax more quickly while smaller exponents yield 
asymptotic values less than Emax. An exponent of 1 reduces the 
equation to the standard hyperbolic Emax model.  
3.5 Michaelis-Menten Equation 
 The effect compartment models are based on a well defined 
equation developed in the early twentieth century to describe the 
fermentation of cane sugar (i.e. sucrose) via hydrolysis into glucose 
and fructose. Michaelis and Menten derived an equation built upon 
earlier work by Henri and others by carrying out definitive experiments 
using the enzyme invertase (Cornish-Bowden 1995). They found that 
the rate of the reaction v was dependent on the substrate (sucrose) 
concentration (a ) and limited by the concentration of enzyme in the 
reaction. The reaction is described by the equation: 
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Figure 5. The Michaelis-Menten equation with illustration of the 
relationship between substrate concentration (a) and velocity of the 
reaction. Km is the concentration of substrate that equaled half the 
maximum velocity of the reaction. 
 
Where: Vmax is the limiting rate for the velocity of the reaction and Km 
is defined as the Michaelis constant describing the substrate 
concentration at which the velocity of the reaction is 1/2 that of Vmax. 
Among the many important contributions to the description of this 
reaction was the measurement of the initial rate of the reaction 
(Vmax/Km) at different sucrose concentrations thereby avoiding 
complicating factor such as reverse reaction, product inhibition and 
inactivation of the enzyme (Cornish-Bowden, 1995). This equation is 
recognized as the fundamental equation of enzyme kinetics and has 
been widely used to describe biological processes in areas outside of 
its original intent. In pharmacological studies, a relationship described 
a
Vmax
0.5V
Km
Initial slope Vmax/Km
2Km
v0
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by this type of equation is referred to as having Michaelis-Menten 
kinetics. 
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Chapter 4 
Nonlinear Mixed Effects Models 
The HRAMG has advanced the estimation of dose-time-response in 
FOB studies by using non-linear mixed effects methods for estimating 
response to chemical exposure. These models capture the dose-
dependent response to chemical exposure while allowing for individual 
subject variation in their natural responses to the measurement 
instrument in the absence of chemical exposure. Increasingly, these 
nonlinear models are evolving to incorporate parameters thought to 
describe well known physiological mechanisms governing response.  
4.1 Toxico-Diffusion Model 
Zhu (2005) used a re-parameterized version of the Michaelis-Menten 
equation for the analysis of the FOB data. 
ttdconcC
ttdconcBtdf
*),(*1
*),(*),( +=  
In this equation  
                         )exp(),( tKV
dtdconc e−=  
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is dependent on the parameter Ke which can be interpreted as the 
elimination rate under intravascular administration (Zhu 2005a). The 
parameter V represents the volume of the circulation system or central 
compartment. In the toxico diffusion function, V is absorbed into the 
parameters B and C in the function. 
This function resembles the Michaelis-Menten equation, but with 
concentration-dependent coefficients B*conc(d,t) and C*conc(d,t).  
The coefficient C can be negative as long as the denominator is 
positive within the experimental range (Zhu 2005a). By incorporating 
a baseline response (A), the equation describes the change in 
response from the initial condition measured prior to exposure 
throughout the time course of the study. Assuming that chemical 
concentration is directly linked to response, rapid elimination of the 
chemical corresponds the function f(d,t) quickly reaching a peak value 
at the time of peak effect (TOPE), and returning tobaseline. However, 
if the compound remains in the subject’s system, f(d,t) may not return 
to the baseline line level, characterizing persistent dose effects.  
This function, relying on a one compartment kinetic paradigm, 
results in a dose independent TOPE. As t varies from 0 toward infinity, 
f(t,d) varies from baseline to a maximum at eKt /1= , then back to 
baseline, irrespective of dose level. Statistical evidence of neurotoxic 
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effects is present when either the coefficient B or C is statistically non-
zero.  
4.2 Parameter Estimation Methods 
 
Implementation of the toxico-diffusion function represents a 
situation where the observed response is predicted based on a 
nonlinear function of the estimated parameters in the model. Often in 
application of these nonlinear models it is advantageous to incorporate 
a random effects parameter in addition to the fixed effects coefficients 
to account for natural variation in biological response to the testing 
instrument. Thus, random effects represent deviations from the 
population average and can enhance parameter estimation and 
hypothesis testing procedures by accounting for a source of variation 
in the data otherwise subjected to the error term. Given the short 
temporal sequences of FOB data, it is rare that the data can 
accommodate more than one random effect even if biologically feasible 
(Zhu 2005a). Models that incorporate both fixed and random 
components are often termed “mixed-effects” models and a detailed 
description of their development and implementation can be found in 
Pinhiero and Bates (2000). These models generally use maximum 
likelihood (ML) methods for parameter estimation. Likelihood functions 
for mixed-effects models are generally complex, and closed form 
solutions are generally not available. Implementation of ML requires 
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iterative numerical procedures such as Newton-Raphson algorithm, the 
EM-algorithm, and more often the combinations of them (Lindstrom 
and Bates 1988). The model fitting techniques used in this thesis rely 
on the Newton-Raphson algorithm. 
4.3 Model Selection and Diagnostics 
There are several important assumptions associated with mixed 
effects models that require validation. Namely, random effects are 
assumed to be normally distributed around a mean of zero; the 
random effects and the error term are assumed to be uncorrelated, 
and the variance is assumed constant across different experimental 
conditions. Choosing the most appropriate model to represent the 
response observed in the data requires both objective criteria and 
sound investigative principle. The Likelihood Ratio Test (LRT) and 
Information Criteria (AIC and BIC: Pinhiero and Bates, 2000) are 
useful tools for guiding appropriate model selection. Significance 
testing using the LRT relies on the Chi-squared distribution (i.e. 
2(log(L1)-log(L2)) ~ 
2
pχ ) , where L1 is likelihood function of the 
expanded model and L2 is the existing model, and p is the number of 
additional parameters in L1 . While this statistic is readily available in 
most computer software packages, the one-sided alternative test may 
require weight adjustments in some cases (Zhu, 2005). Another 
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restrictive requirement of LRT is that one model must be a sub-model 
of the other comparison model. Information Criteria (Akaike, 1973) 
are a generalization to the Likelihood Ratio Test. They add to the 
likelihood ratio a term to penalize the inclusion of excessive terms in 
the model. They do not require one model being a sub-model of the 
other, but do require the models follow the same family of 
distributions. Akaike’s Information Criteria (AIC) and Bayesian 
Information Criteria (BIC) are two popular methods that yield values 
for comparing the goodness of fit of two models. The model with the 
smaller value of AIC and/or BIC is favored. Investigative principles 
include graphical comparisons of the fitted model with the raw data 
and residual plots to check for randomness of error terms. These are 
helpful tools for selecting the appropriate model in conjunction with 
statistical criteria such as the Log-Likelihood Ratio Test (LRT) and 
Information Criteria (AIC and BIC). Graphical tools are useful for 
visualizing not only the shape of the dose-response but also the 
agreement of the predicted and observed responses. Residual plots 
check the assumptions of independent, normally distributed errors and 
identify potential outlying observations.  
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Chapter Five 
Expanding the Toxico-Diffusion Function 
5.1 Biphasic Toxico Diffusion Function 
This thesis generalizes the toxico-diffusion function developed by 
Zhu (2005) to estimate the dose-time-response relationship in which a 
dose-dependent TOPE is observed. The biphasic toxico-diffusion 
function is a modification of the biphasic kinetic equation discussed in 
chapter 3 that accounts for discrepancies between the central and 
effect compartments in pharmacokinetics. Its foundation is the toxico-
diffusion function with the addition of a second exponential term to 
achieve a dose-dependent TOPE. The rate of the second exponential 
term is dependent on dose as well as time. This second exponential 
term forms a complex exponent with the elimination rate either in the 
numerator (Equation A) to describe accelerated TOPE or in the 
denominator (Equation B) to describe the delayed TOPE often 
observed in capacity limited kinetics.  
(A) 
 )*exp(*1
))**exp()*(exp(*),( 0
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e
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(B) 
 
Therefore, these models do require some a priori knowledge of the 
dose-response relationship to select the appropriate model to describe 
dose dependent TOPE. At some point in the time course of chemical 
exposure, assuming Keo >>Ke , the second exponential term of the 
biphasic model reduces to zero and the model reverts to the standard 
toxico-diffusion function.  
 
 
As with the pharmacodynamic models, the biphasic toxico-
diffusion models are not intended to be mechanistic in the literal sense 
of describing actual pharmacologic or kinetic processes. Rather, here 
the purpose of these models is to incorporate pharmacokinetic 
concepts into a mathematical model that allows for a dose-related shift 
in TOPE that may be related to well known pharmacokinetic processes 
such as nonlinear disposition, tissue or protein binding, metabolism or 
clearance kinetics observed in pharmacological and toxicological 
studies (Gabrielsson and Weiner 2000). Irrespective of the actual 
mechanism governing the observed shift in TOPE, these proposed 
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models may be useful for describing the FOB data and elucidating 
dose-response relationships which exhibit dose-dependent TOPE.  
To illustrate the use of the biphasic toxico-diffusion models, 
parathion motor activity counts were chosen as the response variable 
of interest due to an observed shift in the time of maximal response at 
higher dose levels. In the IPCS studies parathion was introduced by 
oral gavage in corn oil solution at doses of 0.85, 1.69, 3.38 and 6.75 
mg/kg. Parathion is readily absorbed through the digestive tract and 
detection in the bloodstream has been reported immediately after oral 
administration (INCHEM 2004). Nonlinear binding of the toxic 
parathion metabolite, paraoxon, has been reported for red blood cells 
(with supra-linear dose-response) and brain tissue (with a sub-linear 
dose-response) (Vogel et al. 2002). Kramer et al. (2002) used a three 
compartment model to describe the pharmacokinetics of Methyl 
Parathion but failed to elucidate the pharmacodynamic properties 
associated with this hazardous organophosphorus pesticide. For the 
model described in this thesis to be related to physiological processes, 
bioavailability is assumed to be 100% and absorption from the 
gastrointestinal tract is assumed to be nearly instantaneous.  
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5.2 Parathion Activity Counts 
Examination of the raw data plots reveal the relationship between 
dose, time and activity counts observed after a single exposure to 
parathion (Figure 6).  These grouped data plots are constructed such 
that the control group is the first graph (starting on the left), followed 
by panels of increasing dose to the right. The x axis is in log scale for 
display purposes only. 
 
 
 
It is apparent that dose increases resulted in changes of the response 
trajectories (Table 1). The two highest dose groups (3.38mg/kg and 
6.75 mg/kg ) appeared to have vastly lower activity counts than the 
lower dose groups. The observed TOPE associated with the higher dose 
groups was 2H compared with a TOPE at 24H for the controls and the 
lowest dose group. 
Figure 6. Observed response in activity counts of rats subjected 
to acute parathion exposure. Note: Panels are arranged in an 
increasing order of dose (0, 0.85, 1.68, 3.38, 6.75) from left to 
right. 
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Table 1. Dose group average activity counts for motor activity counts 
after acute parathion exposure with standard deviation in parenthesis  
Time 
Dose 
0 2 24 168 
0 323.6 (51.3) 225.6 (72.1) 180.2 (71.4) 222.3 (70.0) 
0.85 316.0 (53.2) 217.8 (83.9) 178.9 (76.0) 257.5 (60.5) 
1.69 291.9 (37.5) 207.6 (44.5) 185.5 (59.9) 232.5 (95.8) 
3.38 336.2 (57.8) 139.6 (99.2) 144.0 (42.4) 224.9 (77.9) 
6.75 296.2 (64.1) 15.9 (14.7) 93.6 (49.9) 201.7 (67.7) 
 
These aspects of the observed data suggested that the parathion 
activity count data may allow for an application of the biphasic 
numerator model. Therefore, the biphasic numerator model (equation 
1) was applied the parathion motor activity counts to describe the 
apparent acceleration of TOPE observed in the data.  
5.3 Fitted Response 
The fitted biphasic model predicted a decline in activity counts 
after exposure to parathion, and the predicted trend resembles the 
observed pattern. However, only the intercept A and the rate 
parameter Ke were statistically significant, the slope factors B and C 
and Keo are insignificant (Table 2). A large amount of variation in the 
data was attributable to the between rat variation at baseline and was 
accounted for by a random effect for baseline activity count. The 
random effects had a standard deviation 35.9, about 54% of residual 
standard deviation (Table 2).  
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Figure 7. Fitted response of biphasic numerator model for rats 
subjected to acute parathion exposure. 
Table 2.  Summary of biphasic model fit to parathion activity counts 
Parameter Estimate Standard 
Error 
DF t-value  p-value 
A 258.0129 7.91744 146 32.588 <.0001 
B -72.3701 83.48372 146 -0.867 0.387 
C 0.2265 0.35207 146 0.643 0.521 
Ke 0.1400 0.03561 146 3.931 0.0001 
Keo 0.3198 0.21072 146 1.518 0.131 
Random 
Effects 
Intercept Residual    
 35.93553    65.08784    
 
 
The fitted biphasic model appeared to be a reasonable fit the observed 
data. The fitted dose-response pattern resembles the observed data in 
aspects of TOPE and magnitude of response changes. 
 
 
 
Evidence of a good fit of the model to the data comes through 
examination of the residual plots. Residual plots express the difference 
between the observed and predicted responses, termed “error”. An 
assumption of nonlinear mixed effects models is that the errors are 
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independent and normally distributed. Standardized residual plots for 
the parathion activity counts (Figure 8) suggest that the errors are 
centered on a mean of zero and fairly randomly distributed.  
 
 
 
 
 
 
 
 
 
 
The NLME models further assume that the errors are constant across 
dose group while often in biological settings the variance will increase 
in proportion to the mean response. When there is evidence of non-
constant standard deviation, NMLE can incorporate a separate 
standard deviation to each dose group and verify the resulting model 
improvement using the Likelihood Ratio Test (LRT). The addition of 
dose group specific standard deviations to compensate for 
heteroscedascity did not significantly improve the model fit  according 
to the likelihood ratio test (log(L2)-log(L1)) value of 7.28 and a  
corresponding p-value of 0.122. This suggests that a constant 
standard deviation across dose groups is acceptable.  
Figure 8. Residual plots of biphasic model for rats subjected 
to acute parathion exposure. Note: Panels are arranged in 
an increasing order of dose (0, 0.85, 1.68, 3.38, 6.75) from 
left to right. 
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5.4 Dose-Dependent TOPE 
The fitted model also reveals different times of peak effect 
determined by dose level (Figure 9): the higher dose groups clearly 
had an accelerated TOPE. The TOPE varied from 11.5 hours for the 
lowest dose group (0.85mg/kg) to 7.3 and 7.1 hours for the 
3.38mg/kg and 6.75mg/kg dose groups, respectively. 
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The fitted model can also be examined for each subject after 
accounting for the random effect at baseline (Figure 10). Indeed, the 
predicted model appears to capture individual (red) deviation when 
compared to the population average (blue). 
Figure 9. Dose specific trajectories for biphasic model on rats 
subjected to acute parathion exposure. 
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The biphasic model can be viewed as a generalization of the toxico-
diffusion model to allow for a dose-dependent TOPE. Given that these 
models have this hierarchical structure, Information Criteria and the 
Log Likelihood Ratio test were used to test for improvement in the fit 
of the biphasic model relative to the fit of the toxico diffusion model 
(Figure 11). Both Information Criteria and the Log Likelihood Ratio test 
suggest a significant improvement of the biphasic model overall (Table 
3). Despite the fact that the dose-dependent coefficients (B and C) 
Figure 10. Individual specific trajectories for biphasic model on 
rats subjected to acute parathion exposure. 
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and the second kinetic coefficient Keo in the biphasic model are 
statistically insignificant, due perhaps to limited number of data points 
(in time or subjects) in the experiment, the biphasic model is 
attractive because it permits dose-varying TOPE as indicated by the 
motor activity count data. Further, the magnitude of response 
predicted by the biphasic model was dramatically different between 
the two models with the toxico-diffusion model predicting peak 
response (in this case lowest activity count) of 100 at the highest dose 
level while the biphasic model predicted a peak response (lowest 
activity count) of three; the true response observed in the data (see 
figure 6). Correctly predicting the magnitude of peak effect is 
important as the peak effect could have dramatic implications on 
benchmark dose estimation.  On the grounds of toxicology, it is 
generally accepted that the TOPE is less likely to be a constant. With 
only a limited number of time points (4 in the case of motor activity 
counts) spread over a wide range, however, variance in TOPE is less 
likely to be detectable from the FOB data. Therefore, verification of a 
true dose-related TOPE is difficult because the statistical power in 
detecting the variation in observed TOPE from standard FOB assay 
data is low.        
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Figure 11. Predicted response to parathion by the toxico-diffusion 
model.  
 
 
Table 3. Results of log likelihood (LL) ratio test comparing the toxico-
diffusion (TD) and Biphasic Numerator (BNM) models.  
 
Model DF AIC BIC LL Chi Sq. Pr>Chi.Sq 
TD 6 2297.751 2317.541 -1142.876 
BNM 7 2291.730 2314.818 -1138.865 8.021 0.0046 
 
The analysis thus far has demonstrated that FOB assays using 
scarcely spaced experimental time points will likely fail to generate 
sufficient data for dose-response modeling especially when dose 
varying TOPE’s are considered. The next chapter focuses on 
considering FOB designs that may provide enough information about 
the true dose-response necessary to capture dose-dependent response 
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patterns of neuro-toxicological effects, particularly dose-dependent 
time of peak effects, in a valid and reliable manner.  In the next 
chapter, computer simulation is used to explore the most effective FOB 
design protocols to predicted dose-dependent TOPE using the biphasic 
toxico diffusion model. 
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Chapter 6  
 Simulation 
6.1 Simulation Rationale 
 
While the  biphasic toxico-diffusion model appeared 
advantageous relative to the toxico diffusion model in permitting dose-
dependent TOPE, the parathion motor activity count data leaves some 
uncertainty about the model as the parameter estimates for the B, C 
and Keo were statistically insignificant. This lack of statistical power 
seemed to result from insufficient data generated under the current 
FOB design. Specifically, the sparse spacing of experimental testing 
times is believed to provide insufficient data for model 
parameterization.  Therefore, Monte Carlo simulation was adopted to 
investigate the design protocols necessary to recover the key 
characteristics of dose-dependent response along the time course as 
predicted by the biphasic model. The primary objective of the 
simulation was to investigate the benefits of considering alternative 
time spacing and/or adding additional experimental testing times 
and/or experimental subjects to the FOB design to recover the key 
characteristics of the biphasic model with regard to parameter 
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estimation. Assuming that the biphasic model represents the true 
underlying response of rat motor activity to acute parathion exposure, 
we could construct a dataset through simulation that contained the 
underlying response at a sequence of possible testing times in addition 
to the experimental times in the FOB study. We could also control the 
number of subjects in each dose group. The simulation experiments 
then allowed us to evaluate, empirically, the efficiency of designs with 
various locations and frequencies of testing times as well as with 
additional subjects needed for the biphasic toxico-diffusion model to 
capture the dose and time dependent characteristics of the “true” 
response. 
6.2 Simulation Methods 
We obtained the parameter estimates from fitting the biphasic 
model to the motor activity count data of rats exposed to parathion. 
These estimates were then used as the population (“true”) parameters 
in the biphasic function to define the “true” dose-response model. 
Dose levels remained the same as those used in the original parathion 
experiment. Within the content of simulation, the fitted model 
represents the true underlying mean response to parathion, and the 
random effects and random errors govern variation among rats in a 
given population. Generating simulation datasets required several 
steps:   
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Step 1. Generate the mean underlying dose-time-response curve using 
the biphasic model (with the parameter estimates in Table 1) 
at selected dose and time levels. This step results in average 
response specific to the given dose and time involved in the 
designed experiment (Figure 12).   
Step 2. Add random effects.  To account for each subject’s deviation 
from the average score at baseline, random effects were 
generated for each subject using a normal distribution, 
N(0,σ D), where the standard deviation (σ D ) was taken from 
the estimate (35.94) of the fitted biphasic response model. 
The random effects were added to the mean response at every 
dose-time point in the form of the random intercepts. In the 
present simulation there was one random effect for each rat.  
Step 3. Add random errors. Random errors were generated for each 
individual observation from a normal distribution N(0, σ ε ) and 
added to the mean response to represent measurement 
variation (σ ε = 65.09) around the mean response. 
Step 4. Repeat Steps 1-3 n times to generate data of n rats per dose 
group. This process generates one simulated experiment.  
Step 5. Repeat Step 4 one thousand times to generate 1000 
replications of the experiment.  
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Based on this simulation protocol, we generated motor activity scores 
for n rats in each dose group at a sequence of desired testing times.   
We simulated responses at each of the time points used in the original 
study (i.e. 0,2,24,168) as well as additional points in 4 hour intervals 
between times 4 and 24 (i.e. hours 4, 8,12, 16,20). In this way we 
had information at a multitude of testing times around the time of 
peak effect, which allowed us to identify effective designs for 
recovering key characteristics of the biphasic model.  
The purpose of analyzing these simulated experiments was to 
assess the efficiency of these experiments with respect to recovering 
the “true” underlying dose-response information, specifically dose-
dependent TOPE, with a high level of statistical certainty (power). 
Thus, we first considered two groups of simulation experiments, 4-
time point designs and 5-time point designs with ten subjects per dose 
group. While a larger number of time points are statistically desirable, 
designs with 4-5 time points are more practical and more closely 
follow the EPA neurotoxicity risk guideline (USEPA, 1998).  Intuitively, 
a time point in the neighborhood of the true TOPE would provide the 
most relevant information on the TOPE. Therefore, in the 4-point 
design, we retained three time points, 0, 24, and 168 hours from the 
original design protocol and let the 2nd time point vary between 2 h 
and 24 h. These design variations aim at assessing the efficiency of 
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the original FOB experimental design. In the 5-point design, an 
additional time point between 4 and 24 hour was added to the original 
FOB experiment.  
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In addition to the 4-point and 5-point designs, we also 
considered designs with 6, 7, 8, or even 9 time points for the purpose 
of statistical dose-response modeling. These simulated experiments 
helped illustrate the relative gain of using additional points in 
Figure 12. Theoretical “true” dose-dependent biphasic model 
response between 0 hours and 24 hours. Candidate 
experimental testing times used for simulation are indicated by 
the broken vertical lines 
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increasing statistical power or gaining information on the dose-
response. In order to see the effects of sample size on statistical 
power, we also considered using more subjects (i.e. 20, 30) at each 
dose level under the 4 and 5- time point designs. Note there are three 
5-point designs that did not use 2 hours as an experimental point but 
rather contain 2 testing times between 4 and 12 hours as well as at 
hours 0, 24 and 168.  
One thousand data replicates of each of the 35 design trials 
listed in Table 4 were generated and analyzed to evaluate each design. 
Efficiency of the design was evaluated in the following ways: 
1) The convergence rate - the number of fits on the biphasic 
numerator model that reached successful model convergence out 
of the 1000 replicate trials. 
2) Statistical power: The percentage of times the t statistic for each 
parameter exceeded its 95th-percentile (p-value less than 0.05, 
or type I error at 0.05). 
3) Bias = (Σ ( ˆiφ φ− )/n): The difference between the true model 
parameter and the average of 1000 replications of the parameter 
estimate. 
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4) Mean Squared Error = (Σ ( ˆiφ φ− )/n)2+σ 2: The Bias squared + the 
sample variance of the 1000 replications of the parameter 
estimate. 
5) The Bias and MSE of the Time of Peak Effect (TOPE). 
 
These statistical criteria were used to compare the designs and identify 
the more efficient designs with respect to dose-response modeling of 
the biphasic toxico-diffusion model. It should be noted that the 
assessment of power for any parameter estimate precludes the 
situation that the parameter is not meaningful both biologically and 
mathematically. This is because any parameter can be imposed and 
signified statistically with a sufficiently large dataset. However, the 
case of biphasic model indeed precludes the possibility of statistical 
manifestation. While found to be statistically insignificant in the 
original model fit, the model parameters have inherent importance in 
the model function to describe the response (e.g. initial rate of change 
in response, “half-peak” effect dose,  and dose dependence in TOPE). 
Comparison with different models suggested the magnitude of the 
parameter estimates were non-trivial, but the design was 
underpowered to ascertain the value. Within the context of simulation, 
the scenario of such a statistical manifestation can be plainly excluded 
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because data were generated from the biphasic model and all involved 
parameters are mathematical quantities in existence. 
Table 4. Simulated experimental FOB designs using 10, 20, and 30 
subjects per dose group. Experimental testing times were added 
between 4 and 20 hours. 
 
Testing Times 
(Hours) 
Number of 
Subjects 
Number of 
Time 
Points 
4 time-point 
 designs 
  
0,2,24,168 10 4 
0,4,24,168 10 4 
0,8,24,168 10 4 
0,12,24,168 10 4 
0,16,24,168 10 4 
5 time-point 
 designs 
  
0,2,4,24,168 10,20,30 5 
0,2,8,24,168 10,20,30 5 
0,2,12,24,168 10,20,30 5 
0,2,16,24,168 10,20,30 5 
0,2,20,24,168 10,20,30 5 
Alt. 5 time-point  
designs 
  
0,4,12,24,168 10,20,30 5 
0,8,12,24,168 10,20,30 5 
0,4,8,24,168 10,20,30 5 
Extended time-point 
designs 
  
0,2,4,12,24,168 10 6 
0,2,8,12,24,168 10 6 
0,2,4,8,12,24,168  10 7 
0,4,8,12,16,24,168 10 7 
0,2,4,8,12,16,24,168 10 8 
0,2,4,8,12,16,20,24,168 10 9 
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6.3 Simulation Results 
6.3.1  Four Time Point Designs: Ten Subjects 
In the 4-time point design, only the 2nd point differs from the 
original FOB experiment protocol. The 2nd time point varied from 2 to 
16 hours, the results showed pronounced effect on the power of 
detecting the parameter Keo (Table 5). When the second time point 
was chosen to be hours 8 or 12, the statistical power for the non-zero 
Keo improved from 45 % to approximately 80%. However, for the 
parameters B and C the power of detecting a non-zero value remained 
low, ranging from 0.1% to 15.5%. The convergence rate in fitting the 
biphasic model decreased markedly as the second testing time moved 
past 12 hours. For example, the convergence was only about 72.9% at 
16 hours, suggesting the data did not provide adequate information to 
even fit the model. Note that the shaded row indicates the design that 
appeared to be most beneficial for recovering the true model response.    
Table 5.  Summary of simulated design trials with 10 subjects per dose 
group and 4 testing times.  
   
Cont’d next page 
 
 
4 Point Designs PARAMETER 
 Power (% p<0.05) (average p value of t-statistic) 
Time Points B C Keo Convergence 
(%) 
0,2,24,168 15.5(0.329) 0.0(0.466) 45.5(0.118) 94.1 
0,4,24,168 11.5(0.309) 0.0(0.392) 69.1(0.068) 93.1 
0,8,24,168 5.7(0.259) 0.0(0.329) 81.6(0.057) 88.5 
0,12,24,168 1.2(0.271) 0.0(0.341) 80.5(0.063) 82.6 
0,16,24,168 0.1(0.331) 0.0(0.398) 75.7(0.091) 72.9 
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Table 5 Cont’d 
1) 2nd testing time was selected at various times from 2-16 hours and effects on 
power and statistical significance examined.  
2) Numbers in columns 2, 3, and 4 indicate the percent of time a p value <0.05 
was observed while numbers in parentheses represent the average p_value 
based on 1000 replications. 
3) The first row (design 0,2,24,168) is the true FOB design on which this 
simulation was based  
 
Bias and MSE were also used to evaluate an efficient design for 
parameter estimation using the biphasic model. Bias represents the 
average difference in the location of the parameter estimate while MSE 
represents the imprecision of that estimate across the 1000 
replications of each simulated experimental design. Consistent with the 
results of the power analysis, bias and MSE for the Keo parameter were 
the smallest at 8 hours and therefore represented the best choice of 
testing times within this group of designs (Table 6) for this endpoint.  
However, the bias and MSE in parameters B and C appeared to be the 
smallest when the second testing time was at 16 hours. Convergence 
decreased markedly for designs with the hour 16 being a testing time, 
which may have affected the MSE for this design by eliminating some 
of the larger variations in the parameter estimates. The MSE for the 
hour 8 testing time was not markedly different from the hour 16 
design for parameters B, C and Ke and had a higher convergence rate.  
This lends further support for the 0,8,24,168 design as the best choice 
among the 4 time point designs. In general, the MSE was so large for 
the B parameter that it should be no surprise that statistical 
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significance was not achieved for this parameter in any of these 
designs. In view of the results in Table 6, one can conclude that 4-
point designs did not have the statistical power to reliably detect the 
appropriate biphasic model for this endpoint.  
Table  6. Bias and MSE for each parameter of interest for the 4 time 
point designs with 10 subjects. 
Design Bias_B Bias_C Bias_Ke Bias_Keo 
0,2,24,168 -1.59E+03 8.91E+00 6.05E-03 7.47E-02 
0,4,24,168 -1.76E+04 9.81E+01 1.12E-02 2.88E-02 
0,8,24,168 -1.33E+02 6.59E-01 1.12E-03 -1.89E-02 
0,12,24,168 -1.29E+02 6.48E-01 -1.09E-02 -6.43E-02 
0,16,24,168 -9.87E+01 5.29E-01 -2.80E-02 -1.10E-01 
Design MSE_B MSE_C MSE_Ke MSE_Keo 
0,2,24,168 6.55E+08 2.25E+04 3.03E-03 8.81E-02 
0,4,24,168 7.94E+10 2.50E+06 4.34E-03 3.39E-02 
0,8,24,168 3.53E+05 8.69E+00 3.16E-03 2.10E-02 
0,12,24,168 1.63E+06 3.76E+01 4.52E-03 2.35E-02 
01624168 3.08E+05 8.52E+00 6.59E-03 3.39E-02 
 
 
6.3.2   Five Time Point Designs: Ten Subjects 
Due to the lack of statistical power in parameter estimation in 
the 4-time point designs, we examined the benefits of adding an 
additional testing time. We retained the 4-time points of the FOB 
design and allocated an additional testing time between 4 and 20 
hours. In a second situation of 5-point designs we also removed the 
hour 2 time point and added 2 time points between 4 and 12 hours to 
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see if time points closer to the true TOPE would increase the statistical 
power.  
 The 5-point designs generally improved the power for all 
parameters of interest (Table 7). The average p value for Keo reached 
a level below 0.05, and the power improved to above 80% for designs 
with the additional testing times between 4 and 12 hours. The 
improvement in power was less pronounced when the additional point 
was beyond 16 hours. For parameter C, the power remained at a low 
level of less than 10%. For the B parameter, the power reached a 
highest level of 28% when the added time point was at 16 hours, and 
stayed at a comparable level within the time range of 8 to 20 hours.  
 
Table 7.  Summary of simulated design trials on FOB parathion data 
with 10 subjects per dose group and 5 testing times. 
 
 
1) The experimental testing time (3rd testing time) was adjusted by 4 hour 
intervals and effects on power examined. 
5 Point Designs 
PARAMETER 
 % p<=0.05  (mean) 
Time Points B C Keo 
Convergence 
(%) 
0, 2, 4,  24,  168 21.2(0.220) 2.0(0.303) 80.9(0.030) 97.3 
0, 2, 8,  24,  168 24.5(0.147) 9.8(0.213) 82.4(0.030) 99.0 
0, 2, 12, 24, 168 24.5(0.147) 9.8(0.213) 82.0(0.033) 98.4 
0 ,2, 16, 24, 168 27.7(0.158) 7.4(0.233) 73.5(0.047) 97.2 
0, 2, 20, 24, 168 25.8(0.198) 2.6(0.292) 58.3(0.072) 96.4 
Alternate 5 point 
designs 
    
0, 4,12, 24,168 22.0(0.160) 7.8(0.222) 87.4(0.033) 95.2 
0, 8,12, 24,168 17.6(0.144) 1.6(0.204) 89.6(0.032) 91.3 
0, 4, 8, 24,168 21.2(0.169) 5.4(0.232) 90.4(0.024) 96.4 
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2) Numbers in columns 2, 3, and 4 indicate the percent of time a p value <0.05 
was observed while numbers in parenthesis represent the average p_value 
based on 1000 replications. 
3) The true design on which this simulation was based included actual testing 
times of 0,2,24, and 168 hours. 
 
Interestingly, dropping the hour 2 testing time and adding two testing 
times between 4-12 hours had little effect on the statistical power 
though in one case (0,4,8,24,168) a large bias was introduced (Table 
8). The bias for B, C, and Ke was smallest with the design of 
0,8,12,24,168 hours while the bias of Keo was the smallest with the 
0,4,8,24,168 design.  The MSE was smallest with the 0,8,12,24,168 
design for three of the four parameters of interest.  
Table 8. Bias and MSE for each parameter of interest for the 10 
subject, 5 time point design. 
 
Design Bias_B Bias_C Bias_Ke Bias_Keo 
0,2,4,24,168 -3.50E+02 1.86E+00 1.00E-02 4.11E-02 
0,2,8,24,168 -1.33E+02 6.95E-01 9.53E-03 4.80E-02 
0,2,12,24,168 -1.33E+02 6.93E-01 8.68E-03 4.56E-02 
0,2,16,24,168 -1.23E+02 6.41E-01 5.04E-03 5.52E-02 
0,2,20,24,168 -1.17E+02 6.05E-01 3.89E-03 7.47E-02 
     
0,4,12,24,168 -5.71E+02 3.11E+00 5.77E-03 1.96E-02 
0,8,12,24,168 -6.99E+01 3.58E-01 -4.18E-04 -2.22E-02 
0,4,8,24,168 -1.47E+08 8.49E+05 8.97E-03 1.56E-02 
Design MSE_B MSE_C MSE_Ke MSE_Keo 
0,2,4,24,168 3.39E+07 1.06E+03 1.81E-03 3.43E-02 
0,2,8,24,168 1.28E+06 3.70E+01 9.67E-04 5.17E-02 
0,2,12,24,168 1.28E+06 3.70E+01 1.08E-03 5.22E-02 
0,2,16,24,168 2.94E+06 8.05E+01 1.31E-03 5.20E-02 
0,2,20,24,168 3.55E+05 9.73E+00 1.67E-03 7.02E-02 
     
0,4,12,24,168 2.21E+08 6.78E+03 1.91E-03 3.16E-02 
0,8,12,24,168 1.68E+05 4.05E+00 2.40E-03 1.91E-02 
0,4,8,24,168 2.16E+19 7.22E+14 2.36E-03 2.11E-02 
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6.3.3  Designs with Six – Nine Time Points. 
The results of the 5-time point designs begs the question “How 
many testing times will be enough to achieve required statistical power 
for the B and C parameters and acceptable bias and MSE?”. In an 
attempt to answer this question, we increased the number of testing 
times from 5, to between 6 to 9 points, by adding additional points 
between 0 and 24 hours.  As the number of testing times increased, 
the statistical power improved but even with 9 time points, the 
statistical power was still below 70% for B and 37% for C (Table 9). It 
is clear that as the number of time points increases, the power 
increases generally. Furthermore, fixing the number of time points 
yielded some data more informative than others.  
  Table 9. Summary of simulated experiments with six to nine points 
and 10 subjects per dose group.  
   
PARAMETER 
% p<=0.05  (mean) Time Points (Extended time point 
designs) B C Keo 
Convergence 
(%) 
0,2,4,12,24,168 33.5(0.113) 13.2(0.171) 95.4(0.010) 98.8 
0,2,8,12,24,168 43.7(0.084) 16.1(0.133) 93.2(0.017) 98.8 
0,4,8,12,24,168 34.8(0.101) 12.6(0.152) 93.5(0.019) 96.9 
0,2,4,8,12,24,168  47.4(0.073) 19.7(0.117) 97.3(0.006) 99.2 
0,4,8,12,16,24,168 49.0(0.070) 18.8(0.114) 93.9(0.014) 96.8 
0,2,4,8,12,16,24,168 62.6(0.049) 31.0(0.086) 98.0(0.004) 99.2 
0,2,4,8,12,16,20,24,168 68.3(0.043) 36.6(0.077) 98.0(0.005) 99.0 
 
1) Two experimental testing times were added (3rd and 4th testing times) and 
adjusted by 4 hour intervals and effects on power examined.  
2) Numbers in columns 2, 3, and 4 indicate the percent of time a p value <0.05 
was observed while numbers in parenthesis represent the average p_value 
based on 1000 replications.  
 3) The true design on which this simulation was based included actual testing 
times of 0,2,24, and 168 hours. 
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The bias and MSE were generally reduced as the number of testing 
times increased  for parameters B, C, and Ke, although the smallest 
bias in Keo was attained with the 7 time point design of 
0,4,8,12,24,168 (Table 10) and smallest MSE for Keo was associated 
with the 8 time point design 0,2,4,8,12,16,24,168. Even with the 9 
time point design, the coefficient of variation for parameter B was still 
45% of the average.   
 
Table 10. Bias and MSE for Simulated Experiments with 6 and 9 time 
points and 10 subjects 
 
Design Bias.B Bias.C Bias.Ke Bias.Keo 
0,4,8,12,24,168 -6.00E+01 3.06E-01 6.42E-03 1.37E-02 
0,4,8,12,16,24,168 -7.32E+01 3.96E-01 4.63E-03 1.15E-02 
0,2,4,8,12,24,168 -8.85E+01 4.62E-01 9.12E-03 1.76E-02 
0,2,4,8,12,16,24,168 -4.94E+01 2.58E-01 7.59E-03 1.77E-02 
0,2,4,8,12,16,20,24, 
168 -3.99E+01 2.10E-01 6.37E-03 2.14E-02 
Design MSE.B MSE.C MSE.Ke MSE.Keo 
0,4,8,12,24,168 3.46E+04 8.02E-01 1.22E-03 2.24E-02 
0,4,8,12,16,24,168 8.57E+05 2.74E+01 1.18E-03 1.71E-02 
0,2,4,8,12,24,168 1.29E+06 3.77E+01 7.05E-04 1.69E-02 
0,2,4,8,12,16,24,168 7.05E+04 1.97E+00 5.94E-04 1.44E-02 
0,2,4,8,12,16,20,24, 
168 1.09E+04 2.71E-01 5.82E-04 1.84E-02 
 
 
6.3.4 Designs with Increasing Number of Subjects 
 
 
While the simulations have clearly demonstrated that increasing 
the number of time points and selecting “informative” time points can 
generally improve the efficiency of an experiment, there remains a 
considerable amount of MSE, particularly associated with parameter B. 
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This suggests that while selection of time points is essential in 
soliciting information on the shape of dose-response, to reduce 
variation increasing the number of subjects may also be important. 
Therefore, a second simulation was performed using the 5-point 
experiments with 20 or 30 subjects per dose group.  
 
6.3.5 Five time point designs with twenty subjects 
Adding 10 additional subjects to each dose group resulted in 
pronounced improvement in statistical power for estimating the 
parameters. It is seen from Table 11 that the power for Keo was 
consistently above 95% among all experiments, and the power for 
parameters B and C reached 77% and 44% respectively under the 
design of 0,8,12,24,168 hours.  
Table 11. Summary of simulated design trials on FOB Parathion data 
with 20 subjects per dose group and 5 testing times.  
 
PARAMETER 
 
% p<0.05  (average p value) 
Time Points 
5 Point Design 
(20 subjects per 
dose group) B C Keo 
Convergence 
(%) 
0,2,4,24,168 33.0 (0.104) 10.1(0.168) 98.4 (0.004) 99.4 
0,2,8,24,168 63.8 (0.049) 24.2 (0.089) 98.6 (0.003) 99.8 
0,2,12,24,168 70.3 (0.041) 29.2 (0.081) 96.9 (0.006) 99.5 
0,2,16,24,168 61.5 (0.053) 25.3 (0.100) 96.8 (0.009) 99.6 
0,2,20,24,168 47.7(0.079) 18.2(0.142) 93.7(0.016) 99.0 
     
0,4,12,24,168 64.3(0.048) 28.3 (0.086) 98.2 (0.004) 98.6 
0,8,12,24,168 76.9 (0.036) 43.7 (0.067) 96.4 (0.011) 97.0 
0,4,8,24, 168 57.0(0.056) 25.5 (0.097) 99.4 (0.002) 98.7 
Cont’d next page 
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Table 10 Cont’d 
1) The experimental testing time (3rd testing time) was adjusted and effects on 
power examined.  
2) Numbers in columns 2,3, and 4 indicate the percent of time a p value <0.05 
was observed while numbers in parenthesis represent the average p_value 
based on 1000 replications.  
3) The true design on which this simulation was based included actual testing 
times of 0,2,24, and 168 hours. 
 
Under these 20 subject experiments, bias associated with the 
estimates of B, and C was rather invariant while bias in Ke was 
minimized with the 0, 2, 20, 24, 168 design and Keo was minimized 
with the 0, 2, 8, 24, 168 design. The MSE for the 20 subject designs 
was generally reduced by at least an order of magnitude compared 
with the same designs of half the number of subjects. The smallest 
MSE was achieved with designs where the third time was located at 
either 8 or 12 hours (Table 12). The best statistical properties of the 
Keo parameter again was achieved under a slightly different design 
with time points of 0, 8, 12, 24, 168. While increasing the number of 
subjects per dose group did not reduce bias, it dramatically reduced 
the uncertainty of the statistical quantities as measured by MSE. 
Because of the disparity of statistical power in estimating the 
parameters, we further investigated the case of 30 subjects per dose 
group.   
Table 12. Bias and MSE for each parameter of interest for the 20 
subject, 5 time point design. 
Design Bias.B Bias.C Bias.Ke Bias.Keo 
0,2,4,24,168 -5.39E+01 2.74E-01 8.34E-03 2.03E-02 
0,2,8,24,168 -3.96E+01 2.08E-01 7.67E-03 1.34E-02 
Cont’d next page 
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Table 12 Cont’d 
0,2,12,24,168 -3.20E+01 1.73E-01 5.46E-03 2.61E-02 
0,2,16,24,168 -3.17E+01 1.70E-01 4.83E-03 3.66E-02 
0,2,20,24,168 -3.17E+01 1.68E-01 2.96E-03 4.94E-02 
0,4,12,24,168 -3.53E+01 1.90E-01 5.41E-03 9.84E-03 
0,8,12,24,168 -3.35E+01 1.83E-01 3.29E-03 -2.88E-03 
0,4,8,24,168 -4.29E+01 2.26E-01 7.11E-03 3.03E-03 
Design MSE.B MSE.C MSE.Ke MSE.Keo 
0,2,4,24,168 1.61E+04 3.65E-01 6.46E-04 1.30E-02 
0,2,8,24,168 6.43E+03 1.46E-01 3.81E-04 1.29E-02 
0,2,12,24,168 5.18E+03 1.21E-01 3.82E-04 2.05E-02 
0,2,16,24,168 6.44E+03 1.47E-01 4.22E-04 2.79E-02 
0,2,20,24,168 9.26E+03 2.08E-01 5.88E-04 3.21E-02 
     
0,4,12,24,168 5.68E+03 1.29E-01 6.07E-04 1.00E-02 
0,8,12,24,168 8.01E+03 1.80E-01 9.13E-04 8.36E-03 
0,4,8,24,168 8.10E+03 1.86E-01 6.52E-04 6.69E-03 
 
 
6.3.6 Five-Time Point Designs: Thirty Subjects 
A final simulation was conducted on the parathion data using 30 
subjects per dose group. As expected, adding an additional 20 subjects 
to the original design resulted in greater convergence rates and nearly 
satisfactory statistical power for all parameters. Table 13 clearly shows 
that the design of 0, 8,12,24,168 yielded the largest power for 
parameters B and C. We further note that the power of C is 
particularly sensitive to design whereas B, Ke, and Keo are less so.   
Table 13. Summary of simulated design trials on FOB Parathion data 
with 30 subjects per dose group and 5 testing times.  
 
PARAMETER 
% p<0.05  (mean) 
Time Points 
5 Point Design 
(30 subjects per dose 
group) B C Keo 
Convergence 
(%) 
0,2,4,24,168 50.5(0.057) 21.1(0.103) 100(<0.001) 100 
0,2,8,24,168 93.0(0.016) 73.4(0.038) 99.8(<0.001) 99.9 
0,2,12,24,168 94.6(0.014) 78.2(0.035) 99.9(0.001) 100 
Cont’d next page 
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Table 13 Cont’d     
0,2,16,24,168 89.4(0.021) 56.7(0.049) 99.8(0.002) 99.9 
0,2,20,24,168 70.4(0.039) 35.3(0.081) 99.5(0.003) 99.9 
0,4,12,24,168 92.7(0.016) 73.0(0.037) 97.8(0.002) 98.0 
0,8,12,24,168 97.8(0.009) 92.0(0.023) 97.0(0.004) 98.5 
0,4,8,24,168 88.5 (0.021) 67.3 (0.043) 99.6 (<0.001) 99.9 
 
1) The experimental testing time (3rd testing time) was adjusted by 4 hour 
intervals and effects on power examined.  
2) Numbers in columns 2, 3, and 4 indicate the percent of time a p value <0.05 
was observed while numbers in parenthesis represent the average p_value 
based on 1000 replications. 
3) The true design on which this simulation was based included actual testing 
times of 0,2,24, and 168 hours 
 
We expect that adding additional subjects to the experimental 
design will reduce the MSE but that the relative performance of the 
designs will remain consistent with the results under 20 subjects.  
Indeed, as with the twenty-subject experiments,  the 0,2,20,24,168 
design with 30 subjects retained the smallest bias for parameters B, C, 
and Ke while the 0,8,12,24,168 design has the smallest bias for Keo 
(Table 14). It is intriguing that, except for Ke, bias was reduced under 
the 30-subject designs, although the magnitude was small. A plausible 
explanation is the replication size (1000) of the simulation may not be 
sufficiently large to stabilize the variation of the parameter estimators.  
The design which attained the smallest MSE for Ke was consistent 
with the 20-subject design (i.e. 0, 2, 12, 24, 168). However, the MSE 
for parameters B and C and Keo was slightly different (though the 
same order of magnitude) from the results using 20 subjects. 
Specifically, the smallest MSE for these parameters occurred with the 
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0, 8, 12, 24, 168 design under 30 subjects. This discrepancy may be 
attributed to (1) reduction in bias and (2) non-convergence in 
simulations. Reduction in bias may change the expected relationship 
between MSEs’ of the 20- and 30-subject designs. When a simulated 
experiment resulted in non-convergence in model fitting, the 
underlying extreme value was excluded in the computation of bias and 
MSE. Since the non-convergence rate was slightly higher under the 
20-subject design, it is possible that the designs with the smallest 
observed MSE would no longer be the one if the convergence rate 
improved. Finally, there is a possibility that chance alone was 
responsible for the inconsistent MSE. If this is the reason, increasing 
the size of simulation replication would be helpful. Despite this artifact 
of inconsistency, it is clear that including testing times around the true 
TOPE was most beneficial in recovering the true dose-response profile.   
Table 14. Bias and MSE for each parameter of interest for the 30 
subject, 5 time point design. 
 
Design Bias.B Bias.C Bias.Ke Bias.Keo 
0,2,4,24,168 -4.70E+01 2.41E-01 8.87E-03 6.82E-03 
0,2,8,24,168 -3.21E+01 1.72E-01 6.84E-03 2.15E-03 
0,2,12,24,168 -2.71E+01 1.48E-01 5.63E-03 8.42E-03 
0,2,16,24,168 -2.55E+01 1.39E-01 4.77E-03 1.75E-02 
0,2,20,24,168 -2.53E+01 1.37E-01 3.69E-03 2.99E-02 
0,4,12,24,168 -2.80E+01 1.55E-01 3.50E-03 5.85E-03 
0,8,12,24,168 -2.54E+01 1.43E-01 3.74E-03 -1.21E-03 
0,4,8,24,168 -4.29E+01 2.26E-01 7.11E-03 3.03E-03 
Design MSE.B MSE.C MSE.Ke MSE.Keo 
0,2,4,24,168 1.01E+04 2.30E-01 3.99E-04 4.37E-03 
0,2,8,24,168 3.44E+03 7.98E-02 2.46E-04 4.03E-03 
Cont’d next page 
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Table 14 Cont’d 
0,2,12,24,168 3.33E+03 8.01E-02 2.00E-04 5.67E-03 
0,2,16,24,168 3.44E+03 7.92E-02 2.57E-04 1.12E-02 
0,2,20,24,168 5.43E+03 1.26E-01 3.01E-04 1.32E-02 
0,4,12,24,168 3.52E+03 8.02E-02 6.18E-04 2.18E-02 
0,8,12,24,168 2.21E+03 5.03E-02 4.97E-04 4.97E-03 
0,4,8,24,168 4.73E+03 1.09E-01 2.97E-04 3.55E-03 
 
6.3.7 Bias and MSE in Estimating Time of Peak Effect 
In addition to examining the Bias and MSE associated with the 
parameter estimates it is especially useful for the purposes of 
benchmark dose estimation to investigate efficient designs for 
estimating the TOPE. Since the TOPE is critical to benchmark dose 
estimation, Bias and MSE of the TOPE estimator are useful criteria for 
comparing designs.  The 5 time point designs with 20 and 30 subjects 
per dose group were assessed with respect to identifying the design 
that recorded the smallest Bias and MSE for each dose group specific 
TOPE.  For the both the 20 and 30 subject designs, the Bias was within 
one half hour of the true TOPE for each of the dose groups. The MSE 
appeared relatively invariant to design for all dose groups except for 
the lowest dose group (0.85mg/kg) which had the highest magnitude 
in MSE overall (Figures 13 and 14) and seemed to benefit most from 
designs where the testing times were closest to the true TOPE. This 
lowest dose group is especially important to consider because of its 
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relevance in establishing a Reference Dose used to define safe 
exposure limits.  
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Design Key: 1=0,2,4,24,168; 2=0,2,8,24,168; 3=0,2,12,24,168   
4=0,2,16,24,168; 5=0,2,20,24,168; 6=0,4,8,24,168; 7=0,4,12,24,168;  
8=0,8,12,24,168 
Figure 13.  Bias (Top) and Mean Square Error (Bottom) of the TOPE 
estimator under the 5-time point 20 subject designs.  
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Figure 14. Bias (Top) and Mean Square Error (Bottom) of the TOPE 
estimator under the 5-time point 30 subject designs.  
 
Design Key: 1=0,2,4,24,168; 2=0,2,8,24,168; 3=0,2,12,24,168   
4=0,2,16,24,168; 5=0,2,20,24,168; 6=0,4,8,24,168; 7=0,4,12,24,168;  
8=0,8,12,24,168 
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Confidence intervals around the TOPE estimates were generated for 
each of the 5 time point, 20 and 30 subject replicate design trials to 
compare the ability of each design to recover the true TOPE (Table 
15). As shown by the bias and MSE figures the variability in TOPE 
estimation was largest for the lowest dose group.  As dose levels 
increased, the confidence intervals were within +/- one hour of the 
true TOPE (Table 15). The results of the TOPE analysis indicate that 
the biphasic model predicts the TOPE with validity (small bias) and 
that the reliability of the TOPE estimate (MSE) seems to be dependent 
on the number of subjects as well as the location of testing times, 
especially for the lowest dose group). Testing times located in 
proximity to the true TOPE for each dose group appeared to increase 
the reliability of the estimate for that dose group.  
Table 15. Confidence intervals for dose group specific TOPE for each of 
the 5 time point, 20 subject designs. Confidence intervals were 
generated by calculating the 2.5% and 97.5% of the distribution of 
1000 TOPE estimates for each design. 
 
 Dose Group 
20 Subject 
Designs 
0.85 1.69 3.38 6.75 
0,2,4,24,168 12 (9-15) 9 (8-11) 7 (7-8) 7 (5-8) 
0,2,8,24,168 12 (9-14) 9 (8-10) 7 (7-8) 7 (5-8) 
0,2,12,24,168 12 (9-14) 9 (8-10) 7 (7-8) 7 (5-8) 
0,2,16,24,168 12 (9-14) 9 (8-10) 7 (7-8) 7 (5-8) 
0,2,20,24,168 12 (9-15) 9 (8-11) 7 (7-8) 7 (5-8) 
0,4,8,24,168 12 (10-14) 9 (8-10) 7 (6-8) 7 (5-8) 
0,4,12,24,168 12 (9-14) 9 (8-10) 7 (6-8) 7 (5-8) 
0,8,12,24,168 12 (9-14) 9 (8-10) 7 (6-8) 7 (6-8) 
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Table 16. Confidence intervals for dose group specific TOPE for each of 
the 5 time point, 30 subject designs. Confidence intervals were 
generated by calculating the 2.5% and 97.5% of the distribution of 
1000 TOPE estimates for each design. 
 
 Dose Group 
 
30 Subject 
Designs 
0.85 1.69 3.38 6.75 
0,2,4,24,168 12 (10-15) 9 (8-11) 7 (7-8) 7 (5-8) 
0,2,8,24,168 12 (10-14) 9 (8-10) 7 (7-8) 7 (6-8) 
0,2,12,24,168 12 (9-14) 9 (8-10) 7 (7-8) 7 (6-8) 
0,2,16,24,168 12 (9-14) 9 (8-10) 7 (7-8) 7 (6-8) 
0,2,20,24,168 12 (9-14) 9 (8-10) 7 (7-8) 7 (6-8) 
0,4,8,24,168 12 (9-14) 9 (8-10) 7 (7-8) 7 (6-8) 
0,4,12,24,168 12 (10-14) 9 (8-10) 7 (7-8) 7 (6-8) 
0,8,12,24,168 12 (10-14) 9 (8-10) 7 (6-8) 7 (6-8) 
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Chapter 7 
 
Conclusions 
 
In this thesis we have developed a biphasic toxico-diffusion 
model to describe dose-dependent time of peak effect (TOPE) in 
neurobehavioral toxicity screening studies. The model has been 
applied to a dataset from the IPCS collaborative study testing the 
neurotoxic potential of the chemical parathion using motor activity 
counts. The biphasic model predicted a decrease in motor activity 
counts as dose increased with a dose-accelerated TOPE: 11.5 hrs in 
the lowest dose group to 7.1 hrs in the highest dose group. The 
biphasic model was a significant improvement relative to the fit of the 
toxico-diffusion model according to the LRT as well as AIC and BIC. 
Due to the limited amount of data, however, estimates for parameters 
B and C were not statistically significant. Estimates of TOPE varied 
greatly between the two models with the toxico-diffusion model 
predicting a TOPE irrespective of dose at 26 hours while the biphasic 
model predicted a TOPE between 7-12 hours, decreasing with higher 
dose levels. Further, the magnitude of peak response (activity count at 
the TOPE) was dramatically different between the two models. Under 
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the toxico-diffusion model the minimum activity count was predicted to 
be 100 at the highest dose level, whereas under the biphasic model 
the peak response was predicted to be an activity count of 3 (the 
observed response in the data). This difference in magnitude could 
have dramatic impacts on benchmark dose estimation.  
    The simulation experiments identified the limitations of the 
existing FOB design protocol for eliciting physiologically relevant dose-
response information and explored possible design improvements in 
order to generate adequate data for dose-response modeling. A 
specific focus of the simulation was to investigate the sensitivity of the 
experiments with respect to dose-dependent TOPE. Our results 
suggest that under the present experimental protocol of the FOB 
study, there is a substantial lack of statistical power when fitting a 
model such as the biphasic model. Only when the time spacing is 
adequate will information about the true shape in time be available to 
predict the dose-response relationship with validity. Does-dependent 
TOPE’s cannot be verified if there are only limited time points in the 
experiment. In this regard, the existing protocol of FOB is unlikely to 
generate data that support dose-dependent TOPE. The simulation 
results further demonstrated that the design protocol can be altered to 
gain sensitivity and statistical power by adding additional time points 
and/or additional subjects to each dose group in the experimental 
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design. By adding a fifth experimental testing time point between hour 
2 and 24, the sensitivity of the biphasic model improved with regard to 
estimating the dose-dependent time trajectory (e.g. TOPE) as 
witnessed by the increased model fitting convergence rate. By adding 
an additional time point, there are also more data points leading to an 
increase in statistical power for detecting the kinetic parameter Keo, 
which determines the dose-dependent TOPE. Further increases in 
power can be achieved by adding additional subjects.  It is debatable, 
however, whether it is practical to have at least 30 subjects per dose 
group in these screening tests. In suggesting design protocol 
improvements, consideration must be given to the practicality of any 
suggested design for implementation within the framework of the EPA 
testing guidelines for acute neurotoxicity.  
An objective of the IPSC studies was to validate the study 
protocol across participating laboratories. As a result, several 
laboratories conducted experiments on the same chemical using 
identical methodologies. However, each individual laboratory identified 
the TOPE of the chemical through a pilot study and used that TOPE 
estimate as the second testing time for the FOB experiments. Since 
the definition of motor activity counts and the placement of the 2nd 
testing time were left to the discretion of the individual laboratories, 
there are concerns about pooling data across laboratories for statistical 
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inference. Studies such as the IPCS would benefit from an 
experimental design which standardized the approach to TOPE 
estimation and motor activity counts in such a way that these data 
could be pooled across laboratories. The example below considers 
possible alternatives to the IPCS design that may effectively allow for 
more physiologically relevant information to be obtained without 
substantial investment of additional resources.   
The IPCS collaborative studies rely on TOPE estimates from 
range finding studies using gate and arousal scores; however, there is 
evidence that different functional domains may exhibit different time 
courses following acute chemical exposure (Lammers and Kulig, 1997. 
Presuming that the TOPE for a given endpoint is measured without 
error, testing endpoints in more functional domains would yield a 
range of possible TOPE’s for chemical exposure. This range of TOPE’s 
for the given chemical could be used to guide time point selection.   
For example, even using only gait and arousal scores it is quite 
possible that the TOPE was different for these scores yet only one time 
point was chosen to represent the TOPE for the IPCS studies. As an 
alternative to the design above, a testing time associated with each 
TOPE (in this case 2) could be randomly assigned to participating 
laboratories. The data across laboratories could then be pooled 
resulting in a dataset where testing times for each TOPE estimate were 
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captured while each participating laboratory would only perform the 
experiments using 4 testing times. Mixed models such as those 
developed in this thesis allow for missing information from the 
individual time trajectories that would result from pooling these data. 
This flexibility a critical advantage of using mixed effects models for 
dose-response assessment compared to traditional methods such as 
analysis of variance. A scenario such as the example above could be 
expanded by considering a situation in which 5 metrics were used in 
the pilot studies to represent a neurobehavioral endpoint from each of 
5 functional domains. A range of potential TOPE’s could be established 
from these experiments. Each laboratory could be randomly assigned a 
testing time within the established range of TOPE’s. Once the data 
were pooled, the resulting dataset would have numerous time points 
for analysis; a scenario more consistent with kinetic studies used to 
estimate physiological properties of the time course of a chemical in an 
organism after exposure.  Toyinbo (2004) has shown that for 
functional domain composite scores, the precision of the TOPE 
estimate is somewhat insensitive to the actual time of TOPE but that 
the MSE appeared to be minimized when the time points were chosen 
prior to the actual time of peak effect.  Our findings suggest that 
testing times bracketing the dose-dependent TOPE’s minimized the 
imprecision of the TOPE estimator and increased the power of the 
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model. By adding even two time points bracketing the range of TOPE’s 
from range finding studies, the experimental design would be capable 
of capturing more information for more neurobehavioral endpoints.  
Another possible design protocol would be to choose distinct 
time points for different dose group in anticipation that the TOPE may 
dose-dependent. Since the range finding studies used a single dose for 
the TOPE estimate, if the chemical possesses dose-dependent TOPE, 
obviously a single testing time would capture the TOPE only for that 
dose. If information were available on potential dose-dependent TOPE 
for a given chemical under study, defining dose specific time points for 
the experiment would yield relevant dose-dependent information 
related to TOPE while maintaining the current sampling effort.  
Adding additional subjects in each dose group would also 
improve estimates of the dose group specific average response which 
should increase the statistic power to detect significant response to 
chemical exposure, but only if the testing times are chosen 
appropriately would the benchmark dose estimation procedures be 
improved. 
 This thesis makes several simplifying assumptions in attempting 
to link mathematical models to pharmacologically relevant parameter 
estimates. Bioavailability of oral induced exposure to parathion is 
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assumed to be 100%. Further, absorption from the gastrointestinal 
tract is assumed to be in rapid equilibrium with concentration in the 
plasma compartment. From there it is the distributional delay 
associated with the hypothesized effects compartment that governs 
the dose-dependent TOPE observed in the data. There is some 
evidence that parathion and its toxic metabolite paraoxon is a 
chemical that induces non additive biochemical reactions in 
experimental subjects (INCHEM 2004). The biphasic toxico-diffusion 
imposed this dose-dependent TOPE but further study is necessary to 
validate this as a mechanistic product of parathion exposure.    
The case of delayed TOPE was not illustrated in this thesis but a 
model was presented which may be useful in assessing dose-
dependent TOPE arising from capacity limited kinetics. These 
situations have been observed in the literature (Dayneka et al. 1993, 
Jusko et al.,1995; Krzyzanski and Jusko 1997) though no examples of 
delayed effects with increasing dose were observed in the IPCS data.   
The Nonlinear mixed effects models described in this thesis do 
not stand in isolation for assessment the neurotoxic potential 
associated with chemical exposure. Rather, the models serve to 
support a framework of different tools including hazard 
characterization, exposure assessment, risk characterization as well as 
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dose-response assessment utilized to build consensus on the potential 
risks associated with toxicity of the tested chemical. These tools are 
intended to support and not to replace the expert judgments of 
toxicologists who remain the key to understanding the implications of 
any inference of chemical exposure. This thesis has provided an 
additional tool that can be used in this regard and has illustrated its 
potential benefits when assessing neurotoxic potential of chemical 
exposure. It has further expanded the capability of risk assessment 
researchers to capture the diverse and sometimes complex aspects of 
dose-response relationships and contributed to the EPA’s aims to use 
more physiologically relevant models to predict dose-response 
relationships over the time course of experimental studies. 
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